Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 1,324.00 1,318.00 1,318.60 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 14.1 66,430

GlaxoSmithKline Gets FDA Approval for Blood-Disorder Drug Nucala

25/09/2020 10:18pm

Dow Jones News

Glaxosmithkline (LSE:GSK)
Historical Stock Chart

From Aug 2020 to Oct 2020

Click Here for more Glaxosmithkline Charts.

By Kimberly Chin


GlaxoSmithKline PLC has received the U.S. Food and Drug Administration's approval for the drug Nucala, which treats adult and pediatric patients with hypereosinophilic syndrome, a type of blood disorder.

Nucala will become the first and only targeted biologic treatment to win approval for patients with eosinophil-driven disease in the U.S., the company said. Eosinophils are a type of white blood cell.

The FDA's approval follows a review of data from the company's Phase 3 study, GlaxoSmithKline said. The results showed 50% fewer patients experienced worsening symptoms or required an escalation in treatment compared with the use of a placebo, the company said.

The results were recently published in the Journal of Allergy and Clinical Immunology.

Nucala is currently used as treatment for several other eosinophil-driven diseases.


Write to Kimberly Chin at


(END) Dow Jones Newswires

September 25, 2020 17:03 ET (21:03 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

1 Year Glaxosmithkline Chart

1 Year Glaxosmithkline Chart

1 Month Glaxosmithkline Chart

1 Month Glaxosmithkline Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201029 07:57:48